Rigel Pharmaceuticals (RIGL) Interest Expenses (2010 - 2026)

For the trailing twelve months through Jun 30, 2026, Interest Expenses at Rigel Pharmaceuticals was $5.81 million, down 25.0% year-over-year; for FY2025, it was $7.32 million, down 7.6% from FY2024.

• Annual Interest Expenses shows a five-year compound annual growth rate of 40.2% (FY2020 to FY2025).
• In prior years, Rigel Pharmaceuticals' Interest Expenses was $7.92 million in FY2024 (+15.2%), $6.87 million in FY2023 (+85.4%), $3.71 million in FY2022 (-23.7%) and $4.86 million in FY2021 (+259.2%).
• The Q2 2026 figure stands as the lowest quarterly Interest Expenses since Q2 2022.
• On a year-over-year basis, Interest Expenses has declined in each of the last six quarters, with an average decline of 12.5% over the last eight quarters.
• The strongest year-over-year quarter for Interest Expenses in the past five years was Q2 2023, with growth of 227.2%; the weakest was Q2 2022, with a decline of 67.7%.
• According to Business Quant data, Interest Expenses for the three prior quarters was $1.43 million (Q1 2026), $1.7 million (Q4 2025) and $1.89 million (Q3 2025).